PHARMACEUTICAL COMPOSITION FOR REDUCING THE SYMPTOMS AND DISEASE OF THE RESPIRATORY INFECTION CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), WHICH COMPRISES AT LEAST ONE AGENT THAT NEUTRALISES THE FUNCTION OF THE TSLP AND/OR TSLPR AND/OR OX40L AND/OR CD177 MOLECULES, AND A PHARMACEUTICALLY ACCEPTABLE EXCIPIENT, AND THE USE THEREOF

摘要

The present invention relates to a pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human Metapneumovirus (hMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, wherein the agent is selected from monoclonal antibodies, biological or synthetic molecules. More specifically, the neutralizing agents are humanized anti-TSLP, anti-TSLPR, anti-OX40L and anti-CD 177 monoclonal antibodies. The use of said composition for preparing a medicament for treating or ameliorating the symptoms and disease of patients infected with human Metapneumovirus (hMPV) is also described.